Izgrev

Hydrochlorothiazide and Irbesartan, the active ingredients in Izgrev, are a thiazide diuretic and an angiotensin II receptor blocker presented as an oral tablet for oral use. They work together to lower blood pressure in adults with hypertension.

GNH USA supplies Izgrev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, traceability and responsive technical support throughout the supply chain.

Izgrev, a combined angiotensin II receptor blocker and thiazide diuretic, is indicated for conditions related to elevated blood pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Hypertension requiring combination therapy: provides additive blood pressure control when monotherapy is insufficient. - Hypertension with fluid retention: promotes diuresis while blocking angiotensin II effects, aiding in volume‑dependent pressure reduction.

Like all antihypertensive agents, the irbesartan/hydrochlorothiazide combination may cause adverse reactions.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances such as low potassium - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Allergic reactions including rash or angioedema - Blood cell abnormalities such as leukopenia - Liver function abnormalities

Before prescribing Izgrev, clinicians should evaluate patient history and monitor specific parameters. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Electrolytes: monitor serum potassium and sodium levels regularly. - Concomitant diuretics: adjust dose to prevent excessive diuresis and electrolyte loss. - Pregnancy: avoid use unless clearly needed, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Irbesartan and hydrochlorothiazide may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs: may reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood pressure lowering, risk of hypotension. - Antidiabetic drugs: thiazide may raise blood glucose, requiring dose adjustment. - Antimicrobials such as trimethoprim‑sulfamethoxazole: may increase risk of hyperkalemia.